Delivery Order SPE2DR25D3201-SPE2DR26FT4RD
- Not listed
- The Defense Logistics Agency awarded a $5,441.04 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injections. This is a non-set-aside contract with a completion date of October 30, 2025, and represents a delivery order issued against AmerisourceBergen's larger contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $19,064.54 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on July 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, was competitively awarded with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,348.82 to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on November 24, 2025. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of November 25, 2025, and performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply transaction under the company's broader federal contracting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency (DLA) awarded a $13,570.85 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and a completion date of August 7, 2025. The pharmaceutical product will be performed and delivered from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections valued at $11,887.80. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors, with an order ceiling value of $16,756.44. This firm fixed price delivery order is set to be completed by September 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, demonstrating AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injections. This is a firm fixed-price delivery order valued at $4,007.01, with an ultimate completion date of May 13, 2025. The contract carries no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors with a ceiling value of $4,379.74 and ultimate completion date of September 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open competition. Performance will be conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DR25D3201Indefinite Delivery Contract
- SPE2DR25D3201-SPE2DR26FT4RDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections, valued at $13,589.57 with a completion date of December 12, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major healthcare distributor serving federal procurement needs. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies supporting military healthcare programs globally. AmerisourceBergen's federal contract portfolio demonstrates significant capability in delivering specialty medications across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contracting mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.6k | 12/10/25 |